GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sol-Gel Technologies Ltd (NAS:SLGL) » Definitions » EV-to-EBITDA

SLGL (Sol-Gel Technologies) EV-to-EBITDA : 2.04 (As of Jul. 19, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Sol-Gel Technologies EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sol-Gel Technologies's enterprise value is $7.70 Mil. Sol-Gel Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $3.77 Mil. Therefore, Sol-Gel Technologies's EV-to-EBITDA for today is 2.04.

The historical rank and industry rank for Sol-Gel Technologies's EV-to-EBITDA or its related term are showing as below:

SLGL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.55   Med: -2.36   Max: 109.28
Current: 2.04

During the past 10 years, the highest EV-to-EBITDA of Sol-Gel Technologies was 109.28. The lowest was -10.55. And the median was -2.36.

SLGL's EV-to-EBITDA is ranked better than
64.92% of 459 companies
in the Biotechnology industry
Industry Median: 10.58 vs SLGL: 2.04

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-19), Sol-Gel Technologies's stock price is $8.13. Sol-Gel Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-4.700. Therefore, Sol-Gel Technologies's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Sol-Gel Technologies EV-to-EBITDA Historical Data

The historical data trend for Sol-Gel Technologies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sol-Gel Technologies EV-to-EBITDA Chart

Sol-Gel Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.04 33.69 -4.63 0.19 -0.28

Sol-Gel Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 1.27 -3.71 -0.28 -0.33

Competitive Comparison of Sol-Gel Technologies's EV-to-EBITDA

For the Biotechnology subindustry, Sol-Gel Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sol-Gel Technologies's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sol-Gel Technologies's EV-to-EBITDA falls into.


;
;

Sol-Gel Technologies EV-to-EBITDA Calculation

Sol-Gel Technologies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=7.696/3.766
=2.04

Sol-Gel Technologies's current Enterprise Value is $7.70 Mil.
Sol-Gel Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sol-Gel Technologies  (NAS:SLGL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sol-Gel Technologies's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.13/-4.700
=At Loss

Sol-Gel Technologies's share price for today is $8.13.
Sol-Gel Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.700.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Sol-Gel Technologies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sol-Gel Technologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sol-Gel Technologies Business Description

Traded in Other Exchanges
Address
7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.